Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 18/20 | 0.75 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.75 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.75 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.75 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.75 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.75 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3621825 | 0.93 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Trifluoroacetic Acid SCHEMBL3621832 | 0.93 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3622777 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3622774 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3624673 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3624672 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3627869 | 0.85 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3627865 | 0.85 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6984960 | 0.84 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3627444 | 0.83 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| WO-2008097538-A1 | THERAPEUTIC AGENTS | MERCK & CO., INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324029-A1 | THERAPEUTIC AGENTS | PSEN2, PSEN1, BACE2 | PSEN1 2/4885PSEN2 1/4885APH1B 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.